For patients with diseases caused by certain genetic mutations, tRNA therapy – though still in the experimental stages – ...
While mRNA may be back in the headlines courtesy of Moderna and Merck & Co.'s phase 3 cancer vaccine success, new research ...
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...
Moderna’s vaccine, intismeran, is a personalized neoantigen vaccine. It delivers mRNA that encodes tumor-specific mutations ...
Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine—individually tailored to ...
Moderna (MRNA) stock exploded 177% on melanoma vaccine trial success, marking the biggest S&P 500 gain in 20+ years. Analysts ...
The potential market is what really gets investors’ attention. One forecast puts the global mRNA cancer-vaccine market at roughly $1.8 billion in 2024 and nearly $7.3 billion by 2030, which would ...
Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...
Despite progress in defining functional elements of noncoding DNA, it is still not fully understood. Researchers, using an experiment that elucidated the function of tens of thousands of noncoding ...
If anyone needed a reminder that US health secretary and fervent anti-vaccine advocate Robert F. Kennedy Jr. has no background in science or medicine, look no further than the video he posted on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results